sponsored byAAAS Golden Fund

EurekAlert!, a service of AAAS
Home About us
Advanced Search
20-Aug-2014 18:29
US Eastern Time

Username:

Password:

Register

Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books

Meetings

Multimedia

Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation

Calendar

Submit a Calendar Item

Subscribe/Sponsor

Links & Resources

Portals

RSS Feeds

Accessibility Option On

Options

Portal Home

Glossary

Background Articles

Research Papers

Meetings

Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 801-825 out of 877.

<< < 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 > >>

Public Release: 17-Oct-2012
Journal of Medicinal Chemistry
New malaria drug requires just one dose and appears twice as effective as existing regimen
Scientists are reporting development of a new malaria drug that, in laboratory tests, has been twice as effective as the best current medicine against this global scourge and may fight off the disease with one dose, instead of the multiple doses that people often fail to take. A report on the drug appears in ACS' Journal of Medicinal Chemistry.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 17-Oct-2012
As MDR-TB continues to spread, efforts coordinating TB detection and treatment hold promise
A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance trends around the globe.

Contact: Derek Ambrosino
Derek.ambrosino@tballiance.org
646-541-9416
TB Alliance

Public Release: 17-Oct-2012
Science Translational Medicine
Epigenetic analysis of stomach cancer finds new disease subtypes
Researchers at the Duke-NUS Graduate Medical School in Singapore have identified numerous new subtypes of gastric cancer that are triggered by environmental factors.

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 16-Oct-2012
UNC-led consortium awarded $4 million to train next generation of global health researchers
The University of North Carolina at Chapel Hill is leading a consortium that will help cultivate the next generation of global health clinicians and scientists, offering a 10-month training fellowship at one of 17 sites in 13 countries in Asia, Africa, and South America.
NIH/Fogarty International Center

Contact: Lisa Chensvold
lisa_chensvold@med.unc.edu
919-843-5719
University of North Carolina Health Care

Public Release: 16-Oct-2012
Biophysical Journal
Novel insights into the physical basis of sickle cell disease could lead to better treatments
Sickle cell disease -- the most common inherited blood disorder in the United States -- causes red blood cells to distort into a crescent shape and block small blood vessels. New insights into how these abnormal cells disrupt circulation could lead to more effective treatment strategies, as revealed by a study published by Cell Press in the Oct. 17 issue of Biophysical Journal.

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press

Public Release: 15-Oct-2012
Proceedings of the National Academy of Sciences
Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies. When treatment was administered one hour after infection, all animals survived. Two-thirds of the animals were protected even when the treatment, known as MB-003, was administered 48 hours after infection.
National Institutes of Health, Defense Advanced Research Projects Agency, Transformational Medical Technologies Initiative, Defense Threat Reduction Agency

Contact: Caree Vander Linden
caree.vanderlinden@us.army.mil
US Army Medical Research Institute of Infectious Diseases

Public Release: 15-Oct-2012
Urgent need for tuberculosis vaccines; experts report progress, obstacles in growing drug resistance
Drawing on recent findings of a significant rise in cases of drug-resistant tuberculosis in the UK and globally, top TB researchers at a briefing today in London called for greater focus on the quest for new vaccines--a crucial long-term, cost-effective method for addressing the growing threat.

Contact: Coimbra Sirica
csirica@burnesscommunications.com
44-743-538-4915
Burness Communications

Public Release: 11-Oct-2012
Science
Using cell phone data to curb the spread of malaria
New research that combines cell phone data from 15 million people in Kenya with detailed information on the regional incidence of malaria has revealed how human travel patterns contribute to the disease's spread.
NIH Models of Infectious Disease Agent Study Program, National Science Foundation

Contact: Todd Datz
tdatz@hsph.harvard.edu
617-432-8413
Harvard School of Public Health

Public Release: 10-Oct-2012
Aeras signs agreement with GSK to jointly advance TB vaccine
Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E* adjuvant. This novel research and resource-sharing agreement between the largest non-profit TB vaccine biotech and one of the world's leading research-based pharmaceutical and healthcare companies marks advancement in the race to develop new vaccines against TB, a global infectious disease killer.

Contact: Jamie Rosen
jrosen@aeras.org
301-547-2853
Aeras

Public Release: 10-Oct-2012
How to address mental disorders in developing countries, 'the most neglected of neglected diseases'
Canadian funding of $19.4 million will support 15 landmark projects to improve mental health diagnosis and care in developing countries: "the most neglected of neglected diseases." Many projects address problems in nations ravaged by conflict and disaster as well as poverty. Of almost 450 million people with mental health disorders, over 75% live in developing countries. WHO estimates 85% of those with serious mental disorders in the developing world receive no treatment at all.

Contact: Terry Collins
tc@tca.tc
416-538-8712
Sandra Rotman Centre for Global Health

Public Release: 9-Oct-2012
PLOS Medicine
Most pregnancy-related infections are caused by 4 treatable conditions
In low-and-middle income countries, pregnancy-related infections are a major cause of maternal death, can also be fatal to unborn and newborn babies, and are mostly caused by four types of conditions that are treatable and preventable, according to a review by US researchers published in this week's PLOS Medicine.

Contact: Sumrina Yousufzai
syousufzai@plos.org
415-568-3164
PLOS

Public Release: 8-Oct-2012
Emerging Infectious Diseases
MRSA researchers identify new class of drug effective against superbug
In two separate published studies, researchers at The Ohio State University Wexner Medical Center have discovered a new class of treatment against methicillin-resistant Staphylococcus aureus as well as evidence of a growing need to quickly genotype individual strains of the organism most commonly referred to as the "superbug."
NIH/National Center for Advancing Translational Sciences

Contact: David Crawford
david.crawford@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 5-Oct-2012
Johns Hopkins Bloomberg School of Public Health awards Dean's Medal to William Foege
Michael J. Klag, M.D., M.P.H., dean of the Johns Hopkins Bloomberg School of Public Health, has awarded the Dean's Medal -- the School's highest honor -- to William Foege, M.D., M.P.H.
Johns Hopkins Bloomberg School of Public Health

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health

Public Release: 3-Oct-2012
American Journal of Tropical Medicine and Hygiene
Chloroquine makes comeback to combat malaria
Malaria-drug monitoring over the past 30 years has shown that malaria parasites develop resistance to medicine, and the first signs of resistance to the newest drugs have just been observed. At the same time, resistance monitoring at the University of Copenhagen shows that the previously efficacious drug chloroquine is once again beginning to work against malaria. In time that will ensure cheaper treatment for the world's poor.

Contact: Michael Alifrangis
micali@sund.ku.dk
45-23-45-18-04
University of Copenhagen

Public Release: 2-Oct-2012
Langmuir
Sticky paper offers cheap, easy solution for paper-based diagnostics
Global health researchers are working on cheap systems like a home-based pregnancy test that might work for malaria, diabetes or other diseases. A new chemical technique makes medically interesting molecules stick to regular paper -- a possible route to building such paper-based diagnostics from paper you could buy at an office-supply store.
Washington Research Foundation, University of Washington's Royalty Research Fund

Contact: Hannah Hickey
hickeyh@uw.edu
206-543-2580
University of Washington

Public Release: 2-Oct-2012
Frontiers in Optics 2012
3-D medical scanner: New handheld imaging device to aid doctors on the 'diagnostic front lines'
Engineers have created a new imaging tool for primary care physicians: a handheld scanner that would enable them to image all the sites they commonly examine--such as inner ears or the health of patients' retinas. The device relies on optical coherence tomography and could offer sooner and better diagnoses for common conditions such as diabetes. The team will present their findings at the Optical Society's Annual Meeting, Frontiers in Optics 2012.

Contact: Angela Stark
astark@osa.org
202-416-1443
The Optical Society

Public Release: 2-Oct-2012
WHO prequalifies a new artemisinin-based combination treatment for malaria
Cipla, one of the leading generic pharmaceutical companies, along with the non-profit research and development organization Drugs for Neglected Diseases initiative today announced the prequalification of the fixed dose combination of Artesunate and Mefloquine – ASMQ FDC – by the World Health Organization. This Cipla-manufactured ASMQ FDC is the first artesunate-mefloquine FDC to be prequalified by WHO and is recommended for the treatment of malaria.

Contact: Violaine Dällenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative

Public Release: 2-Oct-2012
PLOS Medicine
Obesity and under-nutrition prevalent in long-term refugees living in camps
A quarter of households in refugee camps in Algeria are currently suffering from the double burden of excess weight and under-nutrition. According to a study published in the journal PLOS Medicine, obesity is an emerging threat to this community, with one in two women of childbearing age being overweight, whilst nutritional deficiencies such as iron-deficiency anemia and stunted growth remain a persistent problem.
European Community Humanitarian Office, UNHCR, UN

Contact: David Weston
d.weston@ucl.ac.uk
44-020-310-83844
University College London

Public Release: 2-Oct-2012
PLOS Medicine
A national mental health policy for Uganda
In another installment of the PLOS Medicine series on Global Mental Health Practice, Joshua Ssebunnya from the Butabika National Referral and Teaching Mental Hospital in Kampala and colleagues describe their work developing a national mental health policy for Uganda.

Contact: Sumrina Yousufzai
syousufzai@plos.org
415-568-3164
PLOS

Public Release: 2-Oct-2012
PLOS Medicine
Both obesity and under-nutrition affect long-term refugee populations
Both obesity and under-nutrition are common in women and children from the Western Sahara living in refugee camps in Algeria, highlighting the need to balance both obesity prevention and management with interventions to tackle under-nutrition in this population, according to a study by international researchers published in this week's PLOS Medicine.

Contact: Sumrina Yousufzai
syousufzai@plos.org
415-568-3164
PLOS

Public Release: 27-Sep-2012
PLOS Pathogens
Genetic sleuthing uncovers deadly new virus in Africa
An isolated outbreak of a deadly disease known as acute hemorrhagic fever, which killed two people and left one gravely ill in the Democratic Republic of Congo in the summer of 2009, was probably caused by a novel virus scientists have never seen before.

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-4608
University of California - San Francisco

Public Release: 27-Sep-2012
Controlling the spread of diseases among humans, other animals and the environment
West Nile virus, Lyme disease and hantavirus are all infectious diseases spreading in animals and in people. Is human interaction with the environment somehow responsible for the increase in incidence of these diseases?

Contact: Cheryl Dybas
cdybas@nsf.gov
703-292-7734
National Science Foundation

Public Release: 27-Sep-2012
International Journal of Critical Infrastructures
Sandia probability maps help sniff out food contamination
Uncovering the sources of fresh food contamination could become faster and easier thanks to analysis done at Sandia National Laboratories' National Infrastructure Simulation and Analysis Center (NISAC).
Department of Homeland Security

Contact: Stephanie Holinka
slholin@sandia.gov
505-284-9227
DOE/Sandia National Laboratories

Public Release: 27-Sep-2012
Lancet
Study highlights the burden of epilepsy in the developing world
The burden of epilepsy in poorer parts of the world could be readily alleviated by reducing the preventable causes and improving access to treatment, according to a review article funded by the Wellcome Trust.
Wellcome Trust

Contact: Jen Middleton
j.middleton@wellcome.ac.uk
44-207-611-7262
Wellcome Trust

Public Release: 26-Sep-2012
GW receives record 5-year, $134 million grant to study type 2 diabetes medications
John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Latarsha Gatlin
lgatlin@gwu.edu
202-994-5631
George Washington University

Showing releases 801-825 out of 877.

<< < 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 > >>